Carisma Therapeutics Presents Breakthrough CAR-M Therapy Data
Carisma Therapeutics Inc. (NASDAQ: CARM), a leading biopharmaceutical company, recently showcased compelling pre-clinical findings regarding its innovative anti-GPC3 in vivo CAR-M (chimeric antigen receptor macrophage and monocyte) therapy. This revolutionary treatment targets hepatocellular carcinoma (HCC), a challenging solid tumor to address. Developed in collaboration with Moderna, Inc. (NASDAQ: MRNA), Carisma's method has exhibited significant promise, leading to excitement in the fields of cancer treatment and immunotherapy.
Pre-Clinical Data Highlights
Robust Anti-Tumor Activity Demonstrated
The recent findings underscore the remarkable efficacy of Carisma's anti-GPC3 CAR-M therapy against GPC3+ tumors. These tumors commonly present in hepatocellular carcinoma, making the development of effective treatment modalities particularly crucial. The approach involves utilizing lipid nanoparticles to deliver mRNA that encodes CARs directly into myeloid cells, promoting an immune response that targets and eliminates cancerous cells.
A Novel Off-the-Shelf Approach
This innovative therapy represents a significant advancement in off-the-shelf cancer treatments, which reduce the complexity and time required for patient-specific therapies. The simplicity of applying this method may allow for faster clinical adoption and improved patient outcomes, significantly enhancing the cancer treatment landscape.
Presentation Details at SITC 2024
At the Society for Immunotherapy of Cancer (SITC) Annual Meeting, slated for November, Carisma will present detailed findings in a poster session. The session will introduce the abstract titled "Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma,” aimed at disseminating vital information about this cutting-edge therapy.
Session Details
Details about the session are as follows:
- Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma
- Publication Number: 329
- Session Date: Friday, November 8, 2024
- Location: Exhibit Halls A B George R. Brown Convention Center
Additional Presentations
Another vital study presented will be the Phase 1, First-in-Human study focusing on autologous monocytes engineered to express an anti-HER2 CAR in HER2-overexpressing solid tumors. Information will be shared at the same session to spotlight advancements in CAR therapies.
About Carisma Therapeutics
Carisma Therapeutics Inc. is committed to changing the way autoimmune diseases and cancer are treated. Its pioneering work to engineer macrophages and monocytes aims to create transformative immunotherapies. These innovative therapies leverage the immune system's power to effectively combat serious diseases.
Operating out of Philadelphia, Carisma's team is dedicated to advancing cancer treatment options through intelligent engineering of immune cells. The company prioritizes its proprietary cell therapy platform, which uniquely harnesses macrophages' abilities, propelling forward advancements in the fight against various diseases.
Frequently Asked Questions
What is CAR-M therapy?
CAR-M therapy involves modifying macrophages and monocytes to enhance their ability to recognize and eliminate cancer cells.
What are the expected outcomes of Carisma's CAR-M therapy?
The therapy aims to demonstrate robust anti-tumor activity and provide a viable treatment option for solid tumors like HCC.
Where will Carisma present their data?
The data will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Which companies are collaborating with Carisma?
Carisma is collaborating with Moderna, Inc. to develop their CAR-M therapy.
What makes Carisma's approach unique?
Carisma's off-the-shelf CAR-M therapy allows for rapid deployment, making cancer treatment more accessible and efficient.
